Novel approaches to vaccine development against HBV.
This review summarizes studies from my laboratory based on two novel approaches towards vaccine development against hepatitis B surface antigen. The first approach deals with the ability of a monoclonal anti-idiotypic antibody to functionally mimic the a determinant of HBsAg. The second approach exploits the strategy of genetically engineering plants so that they can be used as inexpensive alternatives to fermentation systems for the production of candidate vaccine antigens.
Thanavala
Y
Y
Department of Molecular Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
D000595:Amino Acid Sequence; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000097:blood; D000917:Antibody Formation; D000939:Epitopes / Q000276:immunology; D005818:Genetic Engineering; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D030821:Plants, Genetically Modified; D017386:Sequence Homology, Amino Acid; D014614:Vaccines, Synthetic
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000939:Epitopes; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic